Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-masked study of intravitreal VEGF Trap-Eye versus ranibizumab in neovascular age-related macular degeneration
NL-OMON31673Phase 3Active, not recruiting
- Sponsor
- Kendle International
- Start
- Mar 2008
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aflibercept and ranibizumab in exudative macular degeneration (4 arms), sponsored by Kendle International. Primary endpoint: Proportion of subjects maintaining vision at Week 52. Started Mar 2008; status: active, not recruiting.
02
Drugs
afliberceptranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NL-OMON31673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31673.